FY2029 Earnings Forecast for TSE:ONC Issued By HC Wainwright

Oncolytics Biotech Inc. (TSE:ONC) – Equities research analysts at HC Wainwright issued their FY2029 earnings estimates for Oncolytics Biotech in a report issued on Monday, February 3rd. HC Wainwright analyst P. Trucchio expects that the company will post earnings per share of $1.10 for the year. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.41) per share.

Separately, Raymond James raised shares of Oncolytics Biotech to a “moderate buy” rating in a report on Thursday, November 14th.

Oncolytics Biotech Stock Performance

Shares of Oncolytics Biotech stock opened at C$1.02 on Tuesday. The company has a debt-to-equity ratio of 6.09, a current ratio of 4.99 and a quick ratio of 8.86. The firm has a market cap of C$78.40 million, a P/E ratio of -2.68 and a beta of 1.35. The firm has a 50 day simple moving average of C$1.24 and a 200 day simple moving average of C$1.37. Oncolytics Biotech has a fifty-two week low of C$0.98 and a fifty-two week high of C$2.08.

Oncolytics Biotech (TSE:ONC) last issued its quarterly earnings results on Tuesday, November 12th. The company reported C($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of C($0.11) by C($0.01). During the same quarter last year, the business earned ($0.14) EPS.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.